Viridian Therapeutics, Inc.\DE
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
VRDN | US
Overview
Corporate Details
- ISIN(s):
- US60463E1038 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 221 CRESCENT STREET, 2453 WALTHAM
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for patients with serious and rare autoimmune diseases. The company leverages its core expertise in antibody discovery and engineering to develop optimized and potentially best-in-class therapeutics. Viridian's primary development programs target Thyroid Eye Disease (TED), alongside an FcRn portfolio aimed at treating a broad range of autoimmune conditions. The company is dedicated to improving patient care through innovative treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Viridian Therapeutics, Inc.\DE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Viridian Therapeutics, Inc.\DE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Viridian Therapeutics, Inc.\DE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
